Navigation Links
Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
Date:8/5/2008

of 2008, selling, general and administrative expenses were $19.8 million, an increase of $4.1 million over the second quarter of 2007. The increase in selling, general and administrative expenses was primarily due to increased marketing and employee-related expenses to support Nexavar. Selling, general and administrative expenses included $3.4 million of employee stock-based compensation in the second quarter of 2008 compared to $2.9 million for the second quarter of 2007.

Cash, Cash Equivalents and Marketable Securities

As of June 30, 2008, the company had cash, cash equivalents, and current and non-current marketable securities of $471.2 million compared to $469.7 million at December 31, 2007. This increase was primarily due to cash provided by operations in the first half of 2008.

Six-Month Results

For the six months ended June 30, 2008, Onyx recorded net income of $19.9 million, or $0.35 per diluted share, compared with a net loss of $23.0 million, or $0.49 per diluted share, for the same period in 2007. Nexavar net sales, as recorded by Bayer, were $320.4 million and $142.2 million for the six months ended June 30, 2008 and 2007, respectively. Excluding employee stock-based compensation expense, non-GAAP net income for the six months ended June 30, 2008 was $29.4 million, or $0.52 per diluted share, compared to a non-GAAP net loss of $16.4 million, or $0.35 per diluted share for the same period in 2007. A description of the non-GAAP calculations is provided below in the accompanying Reconciliation of GAAP to Non-GAAP Net Income.

Conference Call with Management Today

Onyx's management will host a teleconference and web cast to provide a general business overview and discuss second quarter 2008 financial results. The event will begin at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on August 5, 2008. Interested parties may access a live web cast of the presentation on our website at:


SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Follow us on LinkedIn –Cholesterol ... cholesterol carrier or lipoprotein in the blood. Such tests ... in the body, especially along the walls of blood ... other cardiovascular disorders. Cardiovascular Diseases (CVD) is the leading ... on a regular basis, to assess an individual’s risk ...
(Date:9/30/2014)... 2014 CORD:USE Cord Blood Bank – ... has entered into an Equity and Exclusive Services Agreement ... series of patented technologies for the isolation of human ... Tianhe is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing that ...
(Date:9/30/2014)... Switzerland (PRWEB) September 30, 2014 ... software solutions for drug discovery and related ... FUNGITECT consortium has chosen Genedata Selector as ... sequencing (NGS) data. FUNGITECT is a European ... invasive fungal diseases via individualized anti-fungal drug ...
(Date:9/30/2014)...  KemPharm, Inc., a clinical-stage specialty pharmaceutical company ... new molecular entity (NME) prodrugs, announced today that ... issued U.S. Patent No. 8,816,083 to KemPharm for ... Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydromorphone, ... The patent, which extends through 2032, provides ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... Biomira Inc. (Nasdaq: BIOM ),(TSX: BRA) today ... Officer, is scheduled to present at the BIO ... on Wednesday, October 10. The presentation is ... accessed at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BIOM&item_id=1 ,657575 and ...
... 3 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today ... its clinical development and discovery programs at,two upcoming investor conferences: ... Presentation: Monday, October 8, 2007 at 8:00 a.m. Eastern ... the Carlton Hotel on Madison Avenue in New York ...
... With more than 70 million,Generation Y employees starting ... global workplace, smart companies are paying,attention, providing these ... their wants and needs. (Photo: http://www.newscom.com/cgi-bin/prnh/20071003/AQW903 ... is the global health care company,Abbott, which was ...
Cached Biology Technology:Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences 2Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences 3Abbott Named One of the 'Best Places to Launch a Career' by BusinessWeek 2Abbott Named One of the 'Best Places to Launch a Career' by BusinessWeek 3Abbott Named One of the 'Best Places to Launch a Career' by BusinessWeek 4
(Date:9/29/2014)... research team says recently identified radiation detection properties of ... doors for homeland security and medical advances. , In ... issue of Optics Letters , UT Arlington Physics ... method to fabricate transparent nanoscintillators by heating nanoparticles composed ... is formed. A scintillator refers to a material ...
(Date:9/29/2014)... Scientists at Washington State University have concluded ... Smith apples may help prevent disorders associated ... first to assess these compounds in apple cultivars ... print edition of the journal Food Chemistry ... a good source of these nondigestible compounds but ...
(Date:9/29/2014)... URBANA, Ill. University of Illinois scientists have found ... they,ve found them in a pretty unlikely placethe crushed ... used in jet fuel. , "The bioactive compounds in ... of Pleasure, are a mixture of phytochemicals that ... The seed meal is a promising nutritional supplement because ...
Breaking Biology News(10 mins):UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3An apple a day could keep obesity away 2New way to detox? 'Gold of Pleasure' oilseed boosts liver detoxification enzymes 2
... GA--As water use and runoff regulations become more stringent ... an issue, finding ways to increase the efficiency of ... study contains answers that can help horticultural growers address ... the research study, explained that most often horticultural best ...
... In co-operation with a research group from Singapore, scientists ... molecules in the form of truncated O-glycans aid growth ... able to decode the significance of these truncated O-glycans, ... the journal PNAS , represent an important contribution ...
... recognised diabetes expert. He heads the Institute for Diabetes ... is the scientific director of the Helmholtz Diabetes Center ... Chair of Metabolic Diseases at the Technische Universitt Mnchen ... of the control of fat and sugar metabolism, with ...
Cached Biology News:Sensors allow for efficient irrigation, give growers more control over plant growth 2Specific sugar molecule causes growth of cancer cells 2
...
Histone H2A Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Detects ~14 kDa Histone H2A. It does not cross-react with other Histones. Reacts with human/mouse/rat. Performs w...
Contains L-glutamine...
... Protein (PEBP) does not share significant ... PEBP is expressed in the ... muscle, and stomach. One important ... exerting inhibitory activity against several serine ...
Biology Products: